Loading patent…
OwnerRoland Stoughton, Geert Schmid-Schonbein +2inventors
InventorsROLAND STOUGHTON, GEERT SCHMID-SCHONBEIN, TONY E. HUGLI, ERIK KISTLER
Estimating the term…
Diagnostic methods that rely on the use of one or more assays that assess cellular activation are provided. The assays are performed on whole blood or leukocytes, and indicate individually or in combination the level of cardiovascular cell activation, which is pivotal in many chronic and acute disease states. These results of the assays are used within a clinical framework to support therapeutic decisions such as: further testing for infectious agents, anti-oxidant or anti-adhesion therapy, postponement and optimal re-scheduling of high-risk surgeries, classifying susceptibility to and progression rates of chronic disease such as diabetes, atherogenesis, and venous insufficiency; extreme interventions in trauma cases of particularly high risk and activation-lowering therapies. Also provided is as composition derived from a pancreatic homogenate that contains circulating cell activating factors, which can serve as targets for drug screening to identify drug candidates for use in activation lowering therapies. Methods for lowering cell activation by administering protease inhibitors, particularly serine protease inhibitors, are also provided.
A method of preparing a cell activating composition, comprising:
A method of improving treatment outcome or. reducing risk of treatment, comprising:
A method of treating or preventing disorders mediated by inappropriate cellular activation, comprising administering an effective amount of a protease inhibitor, wherein the amount is effective in lowering cell activation.
An article of manufacture, comprising packaging material and a pharmaceutical composition containing a protease inhibitor, contained within the packaging material, wherein the pharmaceutical composition is effective for lowering cell activation or preventing increased cell activation, and the packaging material includes a label that indicates that the pharmaceutical composition is used for lowering cell activation levels.
A method of diagnosis and treatment, comprising:
A method for measuring cell activation in a subject, comprising:
Dependencies are inferred from the claim text.